Crónicas de autores

Ricardo Nitrini *

Autor invitado por SIIC

No artigo são apresentadas razões para o emprego dos inibidores da acetilcolinesterase na doença de Alzheimer

O TRATAMENTO FARMACOLÓGICO ATUAL DA DOENÇA DE ALZHEIMER DEVE SER EMPREGADO?

Os medicamentos atuais têm, em geral, efeito pequeno, mas em alguns casos o efeito é evidente, com melhora cognitiva, funcional e do comportamento. Não tem sido possível prever quais pacientes vão ter mais benefício com o tratamento, de modo que vale a pena iniciá-lo e observar a resposta.

*Ricardo Nitrini
describe para SIIC los aspectos relevantes de su trabajo
HÁ SENTIDO EM UTILIZAR O TRATAMENTO ATUALMENTE DISPONÍVEL PARA A DOENÇA DE ALZHEIMER?
Archives of Clinical Psychiatry,
33(4):214-217, 2006

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*, São Paulo, Brasil, São Paulo, Brasil
Imprimir nota
Referencias bibliográficas
Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 20(3):CD003154, 2005.
Bauer RM, Tobias B, Valenstein E. Amnesic disorders. In Heilman KM. Valenstein E (Eds). Clinical Neuropsychology. 3rd ed. Oxford University Press, New York, p 523-602, 1993.
Birks J. Cholinesterase Inhibitors for Alzheimer's Disease. Cochrane Database Syst Rev 25;(1):CD005593, 2006.
Bottino CMC. O tratamento de longo-prazo está indicado para pacientes com doença de Alzheimer? Rev Psiq Clin 32(6);341-2: 2005.
Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 8000:1403, 1976.
Davis KL, Mohs RC. Cholinergic drugs in Alzheimer's disease. N Engl J Med 315:1286-7, 1986.
Drachman DA, Leavitt J. Human memory and the cholinergic system. Arch Neurol 30:113-21, 1974.
Engelhardt E, Brucki SMD, Cavalcanti JL et al. Treatment of Alzheimer’s disease: Recommendations and suggestions of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Arq Neuropsiquiatr 63:1104-12, 2005.
Mayor S. NICE recommends drugs for moderate Alzheimer's disease. Br Med J 332(7535):195, 2006.
Mesulam MM, Van Hoesen GW. Acetylcholinesterase-rich projections from the basal forebrain of the Rhesus monkey to neocortex. Brain Res 109:152-7, 1976.
Nitrini R. The cure of one of the most frequent types of dementia: a historical parallel. Alzheimer Dis Assoc Disord 19:156-8, 2005.
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348:1333-41, 2003.
Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315:1241-5, 1986.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317-24, 2004.
Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10:122-6, 1981.
Winblad B, Poritis N. Memantine in severe dementia: Results of the 9M-Best Study (Benefit and Efficacy in Severely Demented Patients during Treatment with Memantine). Int J Geriatr Psychiatry 14:135-46, 1999.
Otros artículos de Ricardo Nitrini

Nitrini R. The cure of one of the most frequent types of dementia: a historical parallel. Alzheimer Dis Assoc Disord 19:156-158, 2005.
Nitrini R, Caramelli P, Bottino CM, Damasceno BP, Brucki SM, Anghinah R. Academia Brasileira de Neurologia. Diagnosis of Alzheimer's disease in Brazil: cognitive and functional evaluation. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Arq Neuropsiquiatr 63:720-727, 2005.
Nitrini R, Caramelli P, Herrera E Jr, De Castro I, Bahia VS, Anghinah R, Caixeta LF, Radanovic M, Charchat-Fichman H, Porto CS, Teresa Carthery M, Hartmann AP, Huang N, Smid J, Lima EP, Takahashi DY, Takada LT. Mortality from dementia in a community-dwelling Brazilian population. Int J Geriatr Psychiatry 20(3):247-253, 2005.
Kawamoto EM, Munhoz CD, Glezer I, Bahia VS, Caramelli P, Nitrini R, Gorjao R, Curi R, Scavone C, Marcourakis T. Oxidative state in platelets and erythrocytes in aging and Alzheimer's disease. Neurobiol Aging 26(6):857-864, 2005.
Nitrini R, Caramelli P, Herrera Junior E, Porto CS, Charchat-Fichman H, Carthery MT, Takada LT, Lima EP. Performance of illiterate and literate nondemented elderly subjects in two tests of long-term memory. J Int Neuropsychol Soc 10:634-638, 2004.
Nishimura AL, Oliveira JR, Mitne-Neto M, Guindalini C, Nitrini R, Bahia VS, De Brito-Marques PR, Otto PA, Zatz M. Lack of association between the brain-derived neurotrophin factor (C-270T) polymorphism and late-onset Alzheimer's disease (LOAD) in Brazilian patients. J Mol Neurosci 22:257-260, 2004.
Nitrini R, Caramelli P, Herrera E Jr, Bahia VS, Caixeta LF, Radanovic M, Anghinah R, Charchat-Fichman H, Porto CS, Carthery MT, Hartmann AP, Huang N, Smid J, Lima EP, Takada LT, Takahashi DY. Incidence of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord 18:241-246, 2004.
Huang N, Marie SK, Livramento JA, Chammas R, Nitrini R. 14-3-3 protein in the CSF of patients with rapidly progressive dementia. Neurology 61:354-357, 2003.
Herrera Jr E, Caramelli P, Silveira ASB, Nitrini R. Epidemiologic survey of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord 16:103-108, 2002.
Nitrini R, Rosemberg S, Passos-Bueno MR, Teixeira da Silva LS, lughetti P, Papadopoulos M, Carrilho PM, Caramelli P, Albrecht S, Zatz M, LeBlanc A. Familial spongiform encephalopathy associated with a novel prion protein gene mutation. Annals of Neurology 42:138-146, 1997.

Para comunicarse con Ricardo Nitrini mencionar a SIIC como referencia:
rnitrini@uol.com.br

Autor invitado
3 de octubre, 2006
Descripción aprobada
23 de marzo, 2007
Reedición siicsalud
7 de junio, 2021

Acerca del trabajo completo
O TRATAMENTO FARMACOLÓGICO ATUAL DA DOENÇA DE ALZHEIMER DEVE SER EMPREGADO?

Título original en castellano
HA SENTIDO EM UTILIZAR O TRATAMENTO ATUALMENTE DISPONIVEL PARA A DOENÇA DE ALZHEIMER?

Autor
Ricardo Nitrini1
1 Médico, Hospital das Clínicas da Faculdade de Medicina, São Paulo, Brasil, Diretor da Unidade de Neurologia Cognitiva

Acceso a la fuente original
Archives of Clinical Psychiatry
http://www.scielo.br/scielo.php?script=sci_serial&pid=0101-6083&nrm=iso&rep=&lng=pt

El artículo se relaciona estrictamente con las especialidades de siicsalud
El artículo se conecta secundariamente con las especialidades
    


ua40317